Breast Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Standard of Care for Metastatic TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Current Trials for Treatment of Early Stage TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Emerging Data on Biomarkers in ES TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
ICI-Based Therapy in TNBC: Immune-Related Adverse Events
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Early Stage TNBC: Phase 3 IMpassion031 Study
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Key Trials in ICI-Based Therapy for Early Stage TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Role of pCR in Early Stage TNBC Management
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Standard of Care for Early-Stage TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.
In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer
New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.
Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.
Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.
FIP200 deletion was found to enhance the efficacy of immune checkpoint inhibition in patients with nonresponsive breast cancer.
Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.
Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.
Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.
Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
Sofia D. Merajver, MD, PhD, discusses the importance of germline testing in patients with breast and ovarian cancer along with how this testing is being used to personalize treatment.
Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.
William J. Gradishar, MD, discusses the current treatment landscape in metastatic HER2-positive breast cancer.
Palbociclib was not found to significantly improve invasive disease-free survival in patients with hormone receptor–positive, HER2-negative early breast cancer who had residual disease following neoadjuvant chemotherapy.
Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5